share_log

Redhill Biopharma | 424B3: Prospectus

Redhill Biopharma | 424B3: Prospectus

Redhill Biopharma | 424B3:募资说明书
美股SEC公告 ·  08/07 09:56

Moomoo AI 已提取核心信息

RedHill Biopharma Ltd., an Israeli-incorporated company, has announced a change in the ratio of its Shares per American Depositary Share (ADS), effective August 22, 2024. The new ratio will be one ADS to ten thousand shares, a significant increase from the previous four hundred shares per ADS. This change was filed under Rule 424(b)(3) with the file number 333-268713. The Bank of New York Mellon, acting as the depositary, certifies ownership of the ADSs, which are now adjusted to represent 10,000 deposited ordinary shares of RedHill Biopharma. The detailed terms and conditions of the American Depositary Receipts (ADRs) are set forth in the deposit agreement dated December 26, 2012, which outlines the rights and obligations of the ADS owners and the depositary. The agreement also...Show More
RedHill Biopharma Ltd., an Israeli-incorporated company, has announced a change in the ratio of its Shares per American Depositary Share (ADS), effective August 22, 2024. The new ratio will be one ADS to ten thousand shares, a significant increase from the previous four hundred shares per ADS. This change was filed under Rule 424(b)(3) with the file number 333-268713. The Bank of New York Mellon, acting as the depositary, certifies ownership of the ADSs, which are now adjusted to represent 10,000 deposited ordinary shares of RedHill Biopharma. The detailed terms and conditions of the American Depositary Receipts (ADRs) are set forth in the deposit agreement dated December 26, 2012, which outlines the rights and obligations of the ADS owners and the depositary. The agreement also specifies the procedures for the surrender, transfer, and withdrawal of the deposited securities. The depositary has the right to amend the form of the Receipts and any provisions of the deposit agreement as necessary, with certain amendments requiring a 30-day notice to the ADS owners. The company has also made provisions for the distribution of dividends, voting rights, and other corporate actions to the ADS owners, subject to the terms of the deposit agreement.
红山生物制药有限公司是成立在以色列的一家公司,宣布从2024年8月22日起,其股票每个美国存托股份(ADS)之比例将发生变化, 新比例为一ADS对应一万股股票,这相比原先每个ADS对应四百股有显著提升。根据333-268713号文件,在规则424(b)(3)下提出了该变更。纽约梅隆银行代表该公司作为托管人,对ADS的所有权进行认证,ADS现已调整为代表红山生物制药存入的10,000股普通股。美国存托凭证(ADRs)的详细条款和条件包括2012年12月26日签署的存款协议,该协议概述了ADS所有者和托管人的权利和义务。该协议还规定了提交、转让和撤回存入证券的程序。托管人有权根据需要修改存储凭证的形式和存款协议的任何规定,某些修改需要提前30天通知ADS所有者。公司也为ADS所有者的分红、投票权和其他公司行动做出了安排,但需符合存款协议的条款。
红山生物制药有限公司是成立在以色列的一家公司,宣布从2024年8月22日起,其股票每个美国存托股份(ADS)之比例将发生变化, 新比例为一ADS对应一万股股票,这相比原先每个ADS对应四百股有显著提升。根据333-268713号文件,在规则424(b)(3)下提出了该变更。纽约梅隆银行代表该公司作为托管人,对ADS的所有权进行认证,ADS现已调整为代表红山生物制药存入的10,000股普通股。美国存托凭证(ADRs)的详细条款和条件包括2012年12月26日签署的存款协议,该协议概述了ADS所有者和托管人的权利和义务。该协议还规定了提交、转让和撤回存入证券的程序。托管人有权根据需要修改存储凭证的形式和存款协议的任何规定,某些修改需要提前30天通知ADS所有者。公司也为ADS所有者的分红、投票权和其他公司行动做出了安排,但需符合存款协议的条款。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息